Bristol-myers Squibb Compnay

Gregory D Brown

Douglas G Batt

William John Pitts

Jingwu Duan

Stephen T Wrobleski

Percy H Carter

Zhonghui Lu

Bingwei Vera Yang

Junqing Guo

Shuqun Lin

John V Duncia

Michael G Yang

John T Hynes

Robert J Cherney

Steven H Spergel

John S Tokarski

Daniel S Gardner

Hai-Yun Xiao

Harold A Mastalerz

Bin Jiang

Hong Wu

Amy C Hart

Andrew J Tebben

Feng Qiu

James Kempson

Lidia M Doweyko

George V De Lucca

Arun Kumar Gupta

Samayamunthula Venkata Satya Arun Kumar Gupta

Rui-Qin Liu

Murali T G Dhar

TG Murali Dhar

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: &#x2014;(CR3R3)2-5-, &#x2014;(CR3R3)x-Y&#x2014;(CR3R3)y-, &#x2014;Y&#x2014;(CR3R3)2-3-Y&#x2014;, &#x2014;CR3R3-Y&#x2014;(CR3R3)2-Y&#x2014;, &#x2014;Y&#x2014;(CR3R3)2-Y&#x2014;CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Tricyclic heterocyclic compounds useful as inhibitors of TNF

Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein. 

Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

The present application describes modulators of MCP-1 or CCR-2 of formula, (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R, R, Rand R, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula, (I) are disclosed. 

Cyclohexenyl modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity

Growing community of inventors

Lansdale, PA, United States of America

Gregory D Brown